Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
Industry | Market Weight | Day Return | YTD Return |
---|---|---|---|
All Industries | 100% | 0.08% | 2.54% |
Drug Manufacturers - General | 33.95% | 0.12% | 7.82% |
Healthcare Plans | 13.06% | 0.07% | -6.66% |
Medical Devices | 12.91% | -0.04% | 4.24% |
Biotechnology | 11.61% | 0.02% | -2.94% |
Diagnostics & Research | 11.42% | 0.08% | 2.46% |
Medical Instruments & Supplies | 6.67% | 0.01% | 3.25% |
Medical Care Facilities | 2.89% | 0.39% | 9.28% |
Drug Manufacturers - Specialty & Generic | 2.81% | 0.10% | -3.70% |
Medical Distribution | 2.33% | 0.02% | 6.58% |
Health Information Services | 2.10% | 0.64% | 6.15% |
Pharmaceutical Retailers | 0.24% | 0.03% | -31.48% |
Note: Percentage % data on heatmap indicates Day Return
All Industries
-
Largest Companies in This Sector
Name | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
---|---|---|---|---|---|---|---|
734.97 | 855.36 | 10.94% | Buy | ||||
492.45 | 566.61 | 7.10% | Buy | ||||
149.27 | 172.98 | 5.63% | Buy | ||||
127.51 | 141.42 | 5.06% | Buy | ||||
163.79 | 183.20 | 4.54% | Buy | ||||
572.38 | 622.29 | 3.42% | Buy | ||||
105.90 | 126.69 | 2.89% | Buy | ||||
248.38 | 271.39 | 2.88% | Buy | ||||
311.29 | 306.20 | 2.62% | Buy | ||||
27.81 | 31.37 | 2.47% | Buy |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
Name | Last Price | Net Assets | Expense Ratio | YTD Return |
---|---|---|---|---|
140.83 | 37.936B | 0.09% | ||
258.02 | 20.174B | 0.10% | ||
132.96 | 6.991B | 0.45% | ||
89.98 | 6.358B | 0.35% | ||
55.49 | 5.241B | 0.40% |
Mutual Fund Opportunities
Name | Last Price | Net Assets | Expense Ratio | YTD Return |
---|---|---|---|---|
210.02 | 47.432B | 0.29% | ||
88.56 | 47.432B | 0.29% | ||
129.08 | 20.174B | 0.10% | ||
92.74 | 15.399B | 0.80% | ||
91.90 | 14.496B | 0.67% |
Healthcare Research
Discover the Latest Analyst and Technical Research for This Sector
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, Zalando poised as a winner; growth looms for Scotts Miracle Gro; how does Buffett defend Berkshire's cash hoard now; and Bio-Rad, Genmab A/S, and Topsports International.
Analyst Report: Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
RatingPrice TargetAnalyst Report: United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
RatingPrice TargetAnalyst Report: Tandem Diabetes Care, Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
RatingPrice Target